Physician profile
Michael C Tompkins
NPI 1013160068
$7,880.47
in general payments reported to CMS, 2019-2025
14 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2021: $18.17 · 2022: $4,808 · 2023: $2,269 · 2024: $235 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,759 · Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,759.21 |
| Food and Beverage | $983.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Orthopedic Systems | $4,218.95 | 2019-2023 | |
| Arthrex, INC. | $3,037.32 | 2022-2023 | |
| Smoky Mountain Surgical LLC | $210.34 | 2024-2025 | |
| Radius Health, INC. | $109.94 | 2025 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $81.44 | 2024-2025 | |
| Stryker Corporation | $79.39 | 2021-2023 | Ortholoc 2 Lapifuse |
| Davol INC. | $23.83 | 2024 | |
| Medartis INC. | $22.80 | 2019 | |
| Smith+Nephew, INC. | $21.95 | 2019 | |
| Depuy Synthes Sales INC. | $18.15 | 2025 | Fibulink, Na |
| Bioventus LLC | $15.21 | 2025 | Exogen Ultrasound Bone Healing System |
| Ferring Pharmaceuticals INC. | $14.87 | 2024 | Euflexxa |
| Horizon Therapeutics Plc | $14.19 | 2022 | |
| Pacira Therapeutics, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.